ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 1452 • ACR Convergence 2024

    Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)

    Timothy Brandon1, Rui Xiao2, Cassandra Muir1, Matthew Stoll3, Daniel Lovell4, Edward Oberle5, Nancy Chauvin6, Michael Francavilla7, Walter Maksymowych8 and Pamela Weiss9, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Alabama at Birmingham, Birmingham, AL, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Nationwide Children's Hospital, Columbus, OH, 6The Imaging Institute @ The Cleveland Clinic, Cleveland, OH, 7Department of Radiology, Whiddon College of Medicine, University of South Alabama, Mobile, AL, 8University of Alberta, Edmonton, AB, Canada, 9Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Trials for patients with juvenile spondyloarthritis (JSpA) and axial disease are scarce. We assessed the responsiveness of measures for use in trials of patients…
  • Abstract Number: 1684 • ACR Convergence 2024

    Autoantibodies to Transcription Factor a Mitochondria Are Associated with Damage Accrual, Malignancy Risk and Mortality in SLE

    Eduardo Gomez1, Daniel Goldman2, Merlin Paz3, Michelle Petri2 and Felipe Andrade4, 1The Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Timonium, MD, 3Johns Hopkins Medicine, Baltimore, MD, 4The Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: We recently identified autoantibodies in SLE that target transcription factor A mitochondrial (TFAM), a critical protein in mitochondrial DNA transcription and packaging1. These autoantibodies…
  • Abstract Number: 2182 • ACR Convergence 2024

    PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results

    Gina Montealegre Sanchez1, Lauren Arrigoni2, Kevin Rubenstein3, Max Wolff4, Mallory Barrix2, C. Jason Liang5, James Bost6, Meghan Delaney7, Luigi Notarangelo8, Karyl Barron9 and Roberta DeBiasi10, and PECOS Study Team, 1Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID),National Institutes of Health (NIH), Bethesda, MD, 2Center for Cancer and Immunology Research (CCIR), Children's National Research Institute, Washington, DC, 3Clinical Monitoring Research Program Directorate (CMRPD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, 4Clinical Research Directorate (CRD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, 5Biostatistics Research Branch, NIAID, NIH, Bethesda, MD, 6Division of Biostatistics and Study Methodology and Center for Translational Research, Children's National Research Institute, Washington, DC, 7Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC, 8Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, Bethesda, MD, 9Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, 10Children's National Hospital and Research Institute, Washington, DC

    Background/Purpose: The long-term sequelae of SARS-CoV-2 infection in children are unknown. PECOS is a large prospective observational cohort study with the main objective to characterize…
  • Abstract Number: 2396 • ACR Convergence 2024

    PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE

    Anna Korogodina1, Erin Sundel1, Yaroslav Markov2, Vasileios Kyttaris3, Julianne O'Connell1 and Suzanne Krishfield1, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Yale School of Medicine, New Haven, 3BIDMC, Boston, MA

    Background/Purpose: SLE-related outcomes are traditionally assessed by clinician-derived measures. However, these assessments often do not fully capture how patients experience their disease. We assessed the alignment…
  • Abstract Number: 0245 • ACR Convergence 2024

    The Impact of COVID-19 and ‘Long COVID’ on Self-Reported Disease Activity, Disability, and Quality of Life in Patients with Inflammatory Arthritis

    Zachary Wallace1, Miao Lin2, Shruthi Srivatsan2, Andrew King2, Xiaosong Wang3, Rathnam Venkat4, Naomi Patel2, Yumeko Kawano5, Abigail Schiff5, Jennifer Hanberg2, Emily Kowalski5, Colebrook Johnson2, Kathleen Vanni3, Zachary Williams2, Grace Qian3, Caleb Bolden2, Kevin Mueller5, Katarina Bade5, Alene Saavedra5 and Jeffrey Sparks6, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4Tufts University School of Medicine, Boston, MA, 5Brigham and Women's Hospital, Boston, MA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: People with rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), and axial spondyloarthritis (axSpA) are at risk for poor COVID-19 outcomes, including…
  • Abstract Number: 0409 • ACR Convergence 2024

    Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis

    Irene Chern1, Jade Singleton2, Xing Wang3 and Jordan Jones4, 1St. Christopher's Hospital for Children, Philadelphia, PA, 2Seattle Children's Hospital, Seattle, 3Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, 4Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: Down syndrome (DS), a disorder caused by triplication of chromosome 21, affects around 1 in 1000 births making it one of the most common…
  • Abstract Number: 0629 • ACR Convergence 2024

    Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus

    Anca Askanase1, Edward Vital2, Oliver Meier3, Armando Turchetta4, Huiyan (Ashley) Mao4, Justine Maller5, Jorge A. Ross Terres6 and Maria Dall'Era7, 1Columbia University Medical Center, New York, NY, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc,, San Francisco, CA, 6Genentech, Inc,, San Francisco, 7UCSF, Corte Madera, CA

    Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
  • Abstract Number: 0791 • ACR Convergence 2024

    Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset

    Caroline Walton1, Forrest Hurley2, Liubov Arbeeva3, Stephen Messier4, Shannon Mihalko4, Jeffrey Katz5, Richard Loeser6, David Hunter7, Leigh Callahan8 and Amanda Nelson2, 1UNC School of Medicine, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3University of North Carolina, Chapel Hill, Carrboro, NC, 4Wake Forest University, Winston Salem, NC, 5Brigham and Women's Hospital, Brookline, MA, 6University of North Carolina, Chapel Hill, NC, 7Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 8University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC

    Background/Purpose: Precision medicine has previously identified subgroups of clinical trial participants with knee osteoarthritis (kOA) that benefit more from a specific intervention than others. We…
  • Abstract Number: 1126 • ACR Convergence 2024

    The Outcomes of Carpal Tunnel Injections and Carpal Tunnel Surgery

    wilmer sibbitt1, dihowm Fatma1, N. SUZANNE Emil1, Maheswari Muruganandam2, Roderick A Fields1, Vangala Adarsh1, Frank O'Sullivan3, Shuhei Hattori4, Frank M Delgado1 and Krystle Tapia1, 1UNM, Albuquerque, NM, 2University of New Mexico, Albuquerque, NM, 3University of New Mexico School of Medicine, Albuquerque, NM, 4University of Hawaii, Hawaii

    Background/Purpose: arpal tunnel syndrome (CTS) is the most common peripheral neuropathy secondary to chronic median nerve compression at the wrist within the space-limited carpal tunnel…
  • Abstract Number: 1468 • ACR Convergence 2024

    Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials

    Diego Benavent1, Victoria Navarro Compán2, Dafne Capelusnik3 and Sofia Ramiro4, 1Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 2La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 3Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 4Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: The ASAS consensus definition of ‘early axial spondyloarthritis (axSpA)’ (axial symptoms ≤ 2 years) was expert-based given the scarcity of evidence1. We conducted a…
  • Abstract Number: 1699 • ACR Convergence 2024

    Anakinra in Giant Cell Arteritis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

    Hubert de Boysson1, Kim Ly2, Loik Geffray3, Thomas Quemeneur4, Eric Liozon5, Holy Bezanahary5, Noemie Le Gouellec4, Alexandra Audemard6, Samuel Deshayes7, Jonathan Boutemy8, Gwénola Maigné8, Nicolas Martin Silva8, Jean-Jacques Parienti8 and Achille Aouba7, 1Caen university Hospital, Caen, France, 2CHU Limoges, limo, France, 3CH Lisieux, Lisieux, France, 4CH Valenciennes, Valenciennes, France, 5CHU Limoges, Limoges, France, 6Tours, Tours, France, 7Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, 8CHU Caen, Caen, France

    Background/Purpose: A previous retrospective series reported the efficacy and tolerance of anakinra (ANK) in giant cell arteritis (GCA) and called for further validation in a…
  • Abstract Number: 2197 • ACR Convergence 2024

    Outcome Measures for the Assessment of Cutaneous and Musculoskeletal Manifestations of Juvenile Systemic Sclerosis: An International Collaborative Scoping Review and Survey of Current Practice

    Amanda Robinson1, Mustafa Çakan2, Simone Appenzeller3, Susan Shenoi4, Meiping Lu5, Betul Sozeri6, Rongjun Zheng5, Priya Bhave7, Natalia Vasquez Canizares8 and Suzanne Li9, and International Juvenile Systemic Sclerosis Outcomes Group (IJOG), 1Division of Pediatric Rheumatology, University of Utah, Salt Lake City, UT, 2Clinic of Pediatric Rheumatology, Zeynep Kamil Women and Children's Diseases Training and Research Hospital, İstanbul, Turkey, 3Unicamp, Campinas, SP, Brazil, 4Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, 5Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China (People's Republic), 6University of Health Sciences, Istanbul, Turkey, 7Hackensack Meridian School of Medicine, Hackensack, NJ, 8Children's Hospital at Montefiore; Albert Einstein College of Medicine;, New York, NY, 9Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare fibrosing autoimmune disease associated with significant morbidity and mortality. Data on treatment strategies is limited, primarily based…
  • Abstract Number: 2402 • ACR Convergence 2024

    Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis

    Marta Mosca1, Karen Costenbader2, Joan Merrill3, Holly Quasny4, Christine Henning5, Steven Bloom6, Julia Harris6, Ciara O’Shea7, Tatsuya Atsumi8 and Ronald Van Vollenhoven9, 1University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 2Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 4GSK, Clinical Sciences, Durham, NC, 5GSK, Global Medical Affairs, Durham, NC, 6GSK, Immunology Biostatistics, Brentford, United Kingdom, 7GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, 8Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 9Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: SLE flares are associated with increased risk of organ damage/mortality; flare prevention is a key treatment goal.1 Initiating treatment earlier has benefits in autoimmune…
  • Abstract Number: 0261 • ACR Convergence 2024

    Clinical Implications, Bacterial Profiles, and Patient Outcomes in Hospitalized Patients with Autoimmune Rheumatic Diseases

    Angel Kevin Garza-Elizondo1, Ana Cecilia Bardan-Inchaustegui2, Pablo Gamez-Siller3, Diana Elsa Flores-Alvarado4, Jorge Esquivel-Valerio5, Jesus Cardenas-de la Garza2, Elsa Catalina Davila-Correa6, Alejandra Jacquelin Osuna-Corrales6, Karla Judith Duran-Villarreal6, Daniela Alejandra Salcedo-Soto7, Derek de Jesus Gauna-Leal6, Andrea Axelle Prado-Prado6, Debanhi Morales-Espronceda6, Nathalia Valdez-Benavides6, Nirvana Amairany González-Ontiveros6 and Dionicio Galarza-Delgado8, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 2Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 3Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, 4Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, 5Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 6Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, 7Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, 8UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Autoimmune rheumatic diseases (ARD) are chronic conditions that affect multiple organ systems. Patients with ARD tend to have a weak immune system due to…
  • Abstract Number: 0496 • ACR Convergence 2024

    Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints

    Nils Steinz1, Tjardo Maarseveen2, Andrew Cope3, John Isaacs4, Aaron Winkler5, Thomas Huizinga6, Yann Abraham7 and Rachel Knevel1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Leiden University Medical Center, Wormerveer, Netherlands, 3King's College London, London, United Kingdom, 4Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 5Pfizer Inc., Cambridge, MA, 6Department of Rheumatology, Leiden University, Leiden, Netherlands, 7Janssen Research and Development, Beerse, Belgium

    Background/Purpose: Patients with RA display different trajectories in the improvement of disease activity. Discerning the RA trajectories, how they differ between patients and which factors…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology